<DOC>
	<DOCNO>NCT01749540</DOCNO>
	<brief_summary>The purpose study evaluate effect ACE-536 patient beta-thalassemia .</brief_summary>
	<brief_title>Study Evaluate Effects ACE-536 Patients With Beta-thalassemia</brief_title>
	<detailed_description>To evaluate proportion β-thalassemia patient erythroid response , define : 1. hemoglobin increase ≥ 1.5 g/dL baseline ≥ 14 day ( absence red blood cell [ RBC ] transfusion ) non-transfusion dependent patient , 2 . ≥ 20 % reduction RBC transfusion burden compare pretreatment transfusion dependent patient .</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<criteria>Key Men woman &gt; =18 year age For dose escalation phase study : document diagnosis βthalassemia intermedia ( transfusion dependent patient must begin regular transfusion age &lt; 4.0 year ) . For expansion cohort : document diagnosis βthalassemia ( include βthalassemia major βthalassemia intermedia ) . Prior splenectomy spleen size &lt; 18 cm long diameter abdominal ultrasound ( dose escalation cohort ) . Anemia , define : ( ) mean hemoglobin concentration &lt; 10.0 g/dL 2 measurement ( one perform within one day prior Cycle 1 Day 1 perform screening period [ Day 28 Day 1 ] ) nontransfusion dependent patient , define receive &lt; 4 unit RBCs within 8 week prior Cycle 1 Day 1 , ( ii ) transfusion dependent , define require ≥ 4 unit RBCs every 8 week ( confirm 6 month prior Cycle 1 Day 1 ) . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 3 x upper limit normal ( ULN ) . Serum creatinine ≤ 1.5 x ULN . Adequate pregnancy avoidance measure . Patients able adhere study visit schedule , understand comply protocol requirement . Understand able provide write informed consent . Key Any clinically significant pulmonary ( include pulmonary hypertension ) , cardiovascular , endocrine , neurologic , hepatic , gastrointestinal , infectious , immunological ( include clinically significant allo autoimmunization ) genitourinary disease consider investigator adequately control prior Cycle 1 Day 1 . Folate deficiency . Symptomatic splenomegaly . Known positive human immunodeficiency virus ( HIV ) , active infectious hepatitis B ( HBV ) active infectious hepatitis C ( HCV ) . Known history thromboembolic event ≥ grade 3 accord National Cancer InstituteCommon Terminology Criteria Adverse Events ( NCICTCAE ) v.4.0 ( current active minor version ) . Ejection fraction &lt; 50 % echocardiogram , MUGA cardiac MRI . Uncontrolled hypertension define systolic blood pressure ( BP ) ≥ 150 mm Hg diastolic BP ≥ 95 mm Hg . Heart failure class 3 high ( New York Heart Association , NYHA ) . QTc &gt; 450 msec screen ECG . Platelet count &lt; 100 x10 ( 9 ) /L &gt; 1,000 x10 ( 9 ) /L . Proteinuria ≥ Grade 2 . Any active infection require parenteral antibiotic therapy within 28 day prior Cycle 1 Day 1 oral antibiotic within 14 day Cycle 1 Day 1 . Treatment another investigational drug device , approve therapy investigational use ≤ 28 day prior Cycle 1 Day 1 , halflife previous investigational product know , within 5 time halflife prior Cycle 1 Day 1 , whichever longer . Transfusion event within 7 day prior Cycle 1 Day 1 . Patients receive plan receive hydroxyurea treatment . Patients must hydroxyurea within 90 day Cycle 1 Day 1 . Splenectomy within 56 day prior Cycle 1 Day 1 . Major surgery ( except splenectomy ) within 28 day prior Cycle 1 Day 1 . Patients must completely recover previous surgery prior Cycle 1 Day 1 . Iron chelation therapy initiate within 56 day prior Cycle 1 Day 1 . Cytotoxic agent , systemic corticosteroid , immunosuppressant , anticoagulant therapy warfarin heparin within 28 day prior Cycle 1 Day 1 ( prophylactic aspirin 100 mg/d permit ) . Pregnant lactating female . History severe allergic anaphylactic reaction hypersensitivity recombinant proteins excipients investigational drug . Prior treatment sotatercept ( ACE011 ) ACE536 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>